Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9432259 | 0.84 | SLC6A4 (0.40) | AKR1B1 | |
| SCHEMBL9535853 | 0.76 | AKR1B1 (0.46) | AKR1B1TDP1 | |
| SCHEMBL9818844 | 0.74 | POLB (0.42) | AKR1B1TDP1 | |
| SCHEMBL9818841 | 0.74 | POLB (0.42) | AKR1B1TDP1 | |
| Urea SCHEMBL10578369 | 0.73 | AKR1B1 (0.43) | AKR1B1TDP1 | |
| SCHEMBL5161004 | 0.71 | PTGDR2 (0.51) | — | |
| SCHEMBL3525961 | 0.66 | KMT2A (0.39) | — | |
| SCHEMBL4627337 | 0.65 | POLB (0.39) | AKR1B1 | |
| SCHEMBL31110943 | 0.65 | PARP1 (0.36) | AKR1B1TDP1 | |
| SCHEMBL14059983 | 0.64 | PBRM1 (0.56) | AKR1B1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| US-5294635-A | Heterocyclic compounds as aldose reductase inhibitors | PFIZER, INC. (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0530198-A1 | HETEROCYCLIC COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1993-03-10 | — | — | EP | disclosed |
| WO-1991015491-A1 | HETEROCYCLIC COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1991-10-17 | — | — | WO | disclosed |
| US-5039672-A | Administering enzyme inhibitors to control diabetes | PFIZER INC. (US) | 1991-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | AKR1B1 1233/4885TDP1 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.